首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry
【24h】

Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry

机译:顶空固相微萃取-气相色谱-质谱法同时测定人体液体中司来吉兰和去甲基司来吉兰

获取原文
获取原文并翻译 | 示例
           

摘要

A method for the simultaneous determination of selegiline and its metabolite, desmethylselegiline, in human whole blood and urine is presented. The method, which combines a fiber-based headspace solid-phase microextraction (SPME) technique with gas chromatography-mass spectrometry (GC-MS), required optimization of various parameters (e.g., salt additives, extraction temperatures, extraction times and the extraction properties of the SPME fiber coatings). Pargyline was used as the internal standard. Extraction efficiencies for both selegiline and desmethylselegiline were 2.0-3.4% for whole blood, and 8.0-13.2% for urine. The regression equations for selegiline and desmethylselegiline extracted from whole blood were linear (r(2) = 0.996 and 0.995) within the concentration ranges 0.1-10 and 0.2-20 ng/ml, respectively. For urine, the regression equations for selegiline and desmethylselegiline were linear (r(2) = 0.999 and 0.998) within the concentration ranges 0.05-5.0 and 0.1-10 ng/ml, respectively. The limit of detection for selegiline and desmethylselegiline was 0.01-0.05 ng/ml for both samples. The lower and upper limits of quantification for each compound were 0.05-0.2 and 5-20 ng/ml, respectively. Intra- and inter-day coefficients of variation for selegiline and desmethylselegiline in both samples were not greater than 8.7 and 11.7%, respectively. The determination of selegiline and desmethylselegiline concentrations in Parkinson's disease patients undergoing continuous selegiline treatment is presented and is shown to validate the present methodology. (c) 2006 Elsevier B.V. All rights reserved.
机译:提出了一种同时测定人全血和尿中司来吉兰及其代谢产物去甲基司来吉兰的方法。该方法将基于纤维的顶空固相微萃取(SPME)技术与气相色谱-质谱(GC-MS)相结合,需要对各种参数(例如盐添加剂,萃取温度,萃取时间和萃取性质)进行优化。 SPME纤维涂层)。使用Pargyline作为内标。司来吉兰和去甲基司来吉兰的提取效率对全血而言均为2.0-3.4%,对尿液而言为8.0-13.2%。从全血中提取的司来吉兰和去甲基司来吉兰的回归方程分别在0.1-10 ng / ml和0.2-20 ng / ml的浓度范围内是线性的(r(2)= 0.996和0.995)。对于尿液,司来吉兰和去甲基司来吉兰的回归方程分别在0.05-5.0和0.1-10 ng / ml的浓度范围内是线性的(r(2)= 0.999和0.998)。两种样品的司来吉兰和去甲基司来吉兰的检出限为0.01-0.05 ng / ml。每种化合物的定量下限和上限分别为0.05-0.2和5-20 ng / ml。两个样品中司来吉兰和去甲基司来吉兰的日内和日间变异系数分别不大于8.7和11.7%。提出了在接受连续司来吉兰治疗的帕金森氏病患者中确定司来吉兰和去甲基司来吉兰的浓度,并证明该方法可验证本方法。 (c)2006 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号